Fulgent Genetics (NASDAQ:FLGT) COO Jian Xie Sells 1,198 Shares

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 1,198 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $29.57, for a total value of $35,424.86. Following the completion of the transaction, the chief operating officer owned 337,889 shares of the company’s stock, valued at approximately $9,991,377.73. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Jian Xie also recently made the following trade(s):

• On Monday, November 24th, Jian Xie sold 681 shares of Fulgent Genetics stock. The shares were sold at an average price of $30.47, for a total transaction of $20,750.07.
• On Wednesday, November 19th, Jian Xie sold 10,000 shares of Fulgent Genetics stock. The stock was sold at an average price of $29.10, for a total transaction of $291,000.00.
• On Wednesday, September 3rd, Jian Xie sold 1,128 shares of Fulgent Genetics stock. The stock was sold at an average price of $22.03, for a total transaction of $24,849.84.

Fulgent Genetics Price Performance

NASDAQ FLGT traded down $1.06 during trading hours on Monday, reaching $28.52. 182,835 shares of the company’s stock traded hands, compared to its average volume of 329,413. Fulgent Genetics, Inc. has a 52-week low of $14.57 and a 52-week high of $31.04. The firm has a 50-day simple moving average of $24.98 and a 200 day simple moving average of $22.06. The firm has a market cap of $881.61 million, a PE ratio of -17.18 and a beta of 0.92.

Fulgent Genetics (NASDAQ:FLGT) last announced its earnings results on Friday, November 7th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.36. Fulgent Genetics had a negative net margin of 16.83% and a negative return on equity of 2.26%. The business had revenue of $84.07 million during the quarter, compared to the consensus estimate of $81.43 million. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. Sell-side analysts forecast that Fulgent Genetics, Inc. will post -0.85 EPS for the current fiscal year.

Institutional Trading of Fulgent Genetics

Large investors have recently made changes to their positions in the stock. Signaturefd LLC lifted its position in Fulgent Genetics by 60.4% during the second quarter. Signaturefd LLC now owns 1,914 shares of the company’s stock valued at $38,000 after purchasing an additional 721 shares during the period. Raymond James Financial Inc. purchased a new stake in Fulgent Genetics during the 2nd quarter valued at $49,000. PNC Financial Services Group Inc. lifted its holdings in shares of Fulgent Genetics by 122.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,562 shares of the company’s stock valued at $60,000 after buying an additional 1,963 shares during the period. Quantbot Technologies LP purchased a new position in shares of Fulgent Genetics in the 3rd quarter worth $61,000. Finally, State of Wyoming boosted its stake in shares of Fulgent Genetics by 111.1% in the 1st quarter. State of Wyoming now owns 6,564 shares of the company’s stock worth $111,000 after buying an additional 3,455 shares during the last quarter. 48.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on FLGT. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulgent Genetics in a report on Wednesday, October 8th. UBS Group upgraded shares of Fulgent Genetics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $20.00 to $30.00 in a research note on Tuesday, August 5th. Piper Sandler raised their price objective on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Wall Street Zen raised shares of Fulgent Genetics from a “hold” rating to a “buy” rating in a report on Saturday, November 15th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $36.00 price target on shares of Fulgent Genetics in a report on Friday, November 14th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Fulgent Genetics currently has an average rating of “Hold” and a consensus target price of $32.00.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.